Literature DB >> 24206602

Targeting therapeutics to the glomerulus with nanoparticles.

Jonathan E Zuckerman1, Mark E Davis.   

Abstract

Nanoparticles are an enabling technology for the creation of tissue-/cell-specific therapeutics that have been investigated extensively as targeted therapeutics for cancer. The kidney, specifically the glomerulus, is another accessible site for nanoparticle delivery that has been relatively overlooked as a target organ. Given the medical need for the development of more potent, kidney-targeted therapies, the use of nanoparticle-based therapeutics may be one such solution to this problem. Here, we review the literature on nanoparticle targeting of the glomerulus. Specifically, we provide a broad overview of nanoparticle-based therapeutics and how the unique structural characteristics of the glomerulus allow for selective, nanoparticle targeting of this area of the kidney. We then summarize literature examples of nanoparticle delivery to the glomerulus and elaborate on the appropriate nanoparticle design criteria for glomerular targeting. Finally, we discuss the behavior of nanoparticles in animal models of diseased glomeruli and review examples of nanoparticle therapeutic approaches that have shown promise in animal models of glomerulonephritic disease.
Copyright © 2013 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug targeting; Glomerulonephritis; Glomerulus; Kidney; Nanoparticles

Mesh:

Year:  2013        PMID: 24206602     DOI: 10.1053/j.ackd.2013.06.003

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  18 in total

1.  Store-operated calcium entry suppressed the TGF-β1/Smad3 signaling pathway in glomerular mesangial cells.

Authors:  Sarika Chaudhari; Weizu Li; Yanxia Wang; Hui Jiang; Yuhong Ma; Mark E Davis; Jonathan E Zuckerman; Rong Ma
Journal:  Am J Physiol Renal Physiol       Date:  2017-06-21

2.  A kidney-selective biopolymer for targeted drug delivery.

Authors:  Gene L Bidwell; Fakhri Mahdi; Qingmei Shao; Omar C Logue; Jamarius P Waller; Caleb Reese; Alejandro R Chade
Journal:  Am J Physiol Renal Physiol       Date:  2016-10-26

3.  Targeting Anti-TGF-β Therapy to Fibrotic Kidneys with a Dual Specificity Antibody Approach.

Authors:  Steve McGaraughty; Rachel A Davis-Taber; Chang Z Zhu; Todd B Cole; Arthur L Nikkel; Meha Chhaya; Kelly J Doyle; Lauren M Olson; Gregory M Preston; Christine M Grinnell; Katherine M Salte; Anthony M Giamis; Yanping Luo; Victor Sun; Andrew D Goodearl; Murali Gopalakrishnan; Susan E Lacy
Journal:  J Am Soc Nephrol       Date:  2017-08-21       Impact factor: 10.121

4.  Selective Nanoparticle Targeting of the Renal Tubules.

Authors:  Ryan M Williams; Janki Shah; Helen S Tian; Xi Chen; Frederic Geissmann; Edgar A Jaimes; Daniel A Heller
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 10.190

Review 5.  Nanomedicines for renal disease: current status and future applications.

Authors:  Nazila Kamaly; John C He; Dennis A Ausiello; Omid C Farokhzad
Journal:  Nat Rev Nephrol       Date:  2016-10-31       Impact factor: 28.314

6.  Targeting kidneys by superparamagnetic allopurinol loaded chitosan coated nanoparticles for the treatment of hyperuricemic nephrolithiasis.

Authors:  Gurpreet Kandav; D C Bhatt; Deepak Kumar Jindal
Journal:  Daru       Date:  2019-11-05       Impact factor: 3.117

7.  siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA.

Authors:  Jonathan E Zuckerman; Aaron Gale; Peiwen Wu; Rong Ma; Mark E Davis
Journal:  Nucleic Acid Ther       Date:  2015-03-03       Impact factor: 5.486

8.  Multifunctional Natural Polymer Nanoparticles as Antifibrotic Gene Carriers for CKD Therapy.

Authors:  Adam C Midgley; Yongzhen Wei; Dashuai Zhu; Fangli Gao; Hongyu Yan; Anila Khalique; Wenya Luo; Huan Jiang; Xiangsheng Liu; Jiasen Guo; Chuangnian Zhang; Guowei Feng; Kai Wang; Xueyuan Bai; Wen Ning; Chao Yang; Qiang Zhao; Deling Kong
Journal:  J Am Soc Nephrol       Date:  2020-08-07       Impact factor: 10.121

Review 9.  Nanomedicines for kidney diseases.

Authors:  Ryan M Williams; Edgar A Jaimes; Daniel A Heller
Journal:  Kidney Int       Date:  2016-06-09       Impact factor: 10.612

10.  Formoterol PLGA-PEG Nanoparticles Induce Mitochondrial Biogenesis in Renal Proximal Tubules.

Authors:  Ernest L Vallorz; Karen Blohm-Mangone; Rick G Schnellmann; Heidi M Mansour
Journal:  AAPS J       Date:  2021-06-24       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.